Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Eli Lilly and Company
Related studies linked through entity extraction aliases.
A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate
- Status
- TERMINATED
- Phase
- PHASE3
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study
- Status
- COMPLETED
- Phase
- PHASE3
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
- Status
- COMPLETED
- Phase
- PHASE2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)
- Status
- COMPLETED
- Phase
- PHASE3
Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Olaratumab in Soft Tissue Sarcoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy
- Status
- COMPLETED
- Phase
- PHASE2
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
- Status
- COMPLETED
- Phase
- PHASE3
A Study in Migraine Prevention
- Status
- TERMINATED
- Phase
- PHASE2
A Study in Second Line Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Tadalafil in Benign Prostatic Hyperplasia
- Status
- COMPLETED
- Phase
- PHASE1
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
- Status
- COMPLETED
- Phase
- PHASE3
A Study in Participants With Diabetic Peripheral Neuropathic Pain in China
- Status
- COMPLETED
- Phase
- PHASE3
An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults
- Status
- COMPLETED
- Phase
- PHASE1
A Bioequivalence (BE) Study in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
- Status
- COMPLETED
- Phase
- PHASE3